JP2001226289A - Hepatic function ameliorative agent - Google Patents
Hepatic function ameliorative agentInfo
- Publication number
- JP2001226289A JP2001226289A JP2000038486A JP2000038486A JP2001226289A JP 2001226289 A JP2001226289 A JP 2001226289A JP 2000038486 A JP2000038486 A JP 2000038486A JP 2000038486 A JP2000038486 A JP 2000038486A JP 2001226289 A JP2001226289 A JP 2001226289A
- Authority
- JP
- Japan
- Prior art keywords
- lactoperoxidase
- milk
- lactoferrin
- liver function
- hepatic function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003908 liver function Effects 0.000 title claims abstract description 30
- 108010023244 Lactoperoxidase Proteins 0.000 claims abstract description 24
- 102000045576 Lactoperoxidases Human genes 0.000 claims abstract description 24
- 229940057428 lactoperoxidase Drugs 0.000 claims abstract description 24
- 102000010445 Lactoferrin Human genes 0.000 claims abstract description 23
- 108010063045 Lactoferrin Proteins 0.000 claims abstract description 23
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims abstract description 23
- 235000021242 lactoferrin Nutrition 0.000 claims abstract description 23
- 229940078795 lactoferrin Drugs 0.000 claims abstract description 23
- 230000000694 effects Effects 0.000 claims abstract description 19
- 235000013305 food Nutrition 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 10
- 235000013361 beverage Nutrition 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 230000001747 exhibiting effect Effects 0.000 abstract 2
- 235000013336 milk Nutrition 0.000 description 12
- 210000004080 milk Anatomy 0.000 description 12
- 239000008267 milk Substances 0.000 description 12
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 8
- 239000000654 additive Substances 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 102000007544 Whey Proteins Human genes 0.000 description 5
- 108010046377 Whey Proteins Proteins 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 235000020124 milk-based beverage Nutrition 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- 235000013618 yogurt Nutrition 0.000 description 4
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 3
- 239000005862 Whey Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 230000005976 liver dysfunction Effects 0.000 description 3
- -1 lysine and arginine Chemical class 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000194020 Streptococcus thermophilus Species 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000000909 electrodialysis Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000027700 hepatic dysfunction Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000020185 raw untreated milk Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- ATYSZLKTHMZHJA-UXLSSDPBSA-N (3R,4R,5S,6R)-6-(hydroxymethyl)-2-[(3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-2,3,4-triol Chemical compound C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)C1(O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO ATYSZLKTHMZHJA-UXLSSDPBSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 230000000513 bioprotective effect Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000015155 buttermilk Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000020974 cholesterol intake Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000030247 mild fever Diseases 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 235000020254 sheep milk Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、ラクトパーオキシ
ダーゼやラクトフェリンを有効成分とする肝機能改善剤
に関する。また、本発明はラクトパーオキシダーゼやラ
クトフェリンを配合して肝機能改善作用を付与した飲食
品に関する。TECHNICAL FIELD The present invention relates to a liver function improving agent containing lactoperoxidase or lactoferrin as an active ingredient. In addition, the present invention relates to a food or drink having a liver function improving effect by blending lactoperoxidase or lactoferrin.
【０００２】[0002]
【従来の技術】近年、食生活の欧米化に伴い、脂肪、特
に動物性脂肪摂取量の増加、また、それに伴うコレステ
ロール摂取量の増加が顕著である。さらに、栄養バラン
スの偏りやアルコール摂取などにより、代謝を司る肝臓
への負担は大きくなっている。肝臓は、循環機能、***
機能、代謝機能、保護・解毒機能及び血液学的機能を有
しており、そのいずれかの機能に障害が生じると、疲労
感、倦怠感、食欲不振、黄疸及び微熱を始めとする肝機
能障害に特有の諸症状が顕現することとなる。2. Description of the Related Art In recent years, with the westernization of dietary habits, the intake of fat, particularly animal fat, and the accompanying increase in cholesterol intake have been remarkable. In addition, the burden on the liver, which controls metabolism, is increasing due to the imbalance in nutrition and alcohol intake. The liver has circulatory, excretory, metabolic, protective / detoxifying, and hematological functions.If any of these functions is impaired, fatigue, malaise, anorexia, jaundice, and mild fever And various symptoms specific to liver dysfunction will appear.
【０００３】一方、ラクトパーオキシダーゼは、乳中に
存在し、ヘム鉄を含む分子量約８万の糖タンパク質であ
るが、その詳細な構造は未だ明らかにされていない。ラ
クトパーオキシダーゼの利用に関しては、老化防止剤
（特開平5-124980号公報）、低う蝕栄養組成物（特開平
9-107917号公報）、動物の皮膚病治療剤（特開平7-2330
86号公報）などが知られているが、肝機能改善作用を有
することは未だ明らかにされておらず、肝機能を改善す
る目的では利用されていない。また、ラクトフェリン
は、乳中に存在する分子量約８万の糖タンパク質であ
り、２つの領域（ＮロープとＣロープ）を有し、それぞ
れが１原子の鉄をキレート結合する性質を持つ。ラクト
フェリンの利用に関しては、歯周病の治療・予防用医薬
組成物（特開平5-279266号公報）、生体防御能賦活剤
（特開平6-145068号公報）、感染防御剤（特開平 10-25
9137号公報）等が知られているが、肝機能改善作用を有
することは未だ明らかにされておらず、肝機能を改善す
る目的では利用されていない。[0003] On the other hand, lactoperoxidase is a glycoprotein having a molecular weight of about 80,000 containing heme iron and present in milk, but its detailed structure has not yet been elucidated. Regarding the use of lactoperoxidase, an anti-aging agent (JP-A-5-124980), a low carious nutrition composition (JP-A-5-124980)
No. 9-107917), a therapeutic agent for animal skin diseases (JP-A-7-2330)
No. 86) is known, but it is not yet clarified to have a liver function improving effect, and is not used for the purpose of improving liver function. Lactoferrin is a glycoprotein having a molecular weight of about 80,000 that is present in milk, has two regions (N rope and C rope), and has the property of chelating a single iron atom. Regarding the use of lactoferrin, pharmaceutical compositions for treatment and prevention of periodontal disease (JP-A-5-279266), bioprotective agents (JP-A-6-145068), and infection-protecting agents (JP-A-10-1998) twenty five
No. 9137) is known, but it is not yet clarified to have a liver function-improving effect, and is not used for the purpose of improving liver function.
【０００４】[0004]
【発明が解決しようとする課題】本発明は、肝機能障害
の改善という観点で、安全性が高く日常的に摂取が可能
な薬剤や飲食品を提供することを課題とする。SUMMARY OF THE INVENTION An object of the present invention is to provide a drug or food or drink which is safe and can be taken on a daily basis from the viewpoint of improving liver dysfunction.
【０００５】[0005]
【課題を解決するための手段】本発明者らは、肝機能障
害の改善や肝機能低下の予防に有効な物質を探索してい
る過程で、ラクトパーオキシダーゼとラクトフェリンに
肝機能改善の有効な作用があることを見出し、本発明を
完成させるに至った。すなわち、四塩化炭素を用いてラ
ットに肝機能障害を生じせしめ、その変動する血清中の
生化学マーカー値を改善の指標として、肝機能改善作用
を有する物質を探索した結果、ラクトパーオキシダーゼ
及びラクトフェリンにその作用があることを確認した。Means for Solving the Problems In the course of searching for a substance that is effective in improving liver function disorder and preventing liver function deterioration, the present inventors have found that lactoperoxidase and lactoferrin are effective in improving liver function. They have found that they have an effect, and have completed the present invention. That is, hepatic dysfunction was caused in rats using carbon tetrachloride, and as a result of searching for a substance having hepatic function improving action using the fluctuating serum biochemical marker value as an index of improvement, lactoperoxidase and lactoferrin were determined. Has been confirmed to have that effect.
【０００６】[0006]
【発明の実施の形態】以下、本発明を詳細に説明する。
本発明で使用されるラクトパーオキシダーゼ及びラクト
フェリンは、牛乳、人乳、山羊乳、羊乳等の哺乳動物の
乳を原料とするものである。ラクトパーオキシダーゼ及
びラクトフェリンは、リジン、アルギニン等の塩基性ア
ミノ酸を多く含み、総称して塩基性タンパク質と呼ばれ
ることもある。この塩基性タンパク質は、脱脂乳や乳清
等の乳原料を陽イオン交換樹脂を用いて精製することで
得ることができる。乳からラクトパーオキシダーゼやラ
クトフェリンをそれぞれ分離、精製した後、必要量に応
じてそれぞれを配合することもできるが、特に、牛乳の
脱脂乳や乳清を原料として得られるラクトパーオキシダ
ーゼ及びラクトフェリンを含む塩基性タンパク質画分を
利用することが、経済性の面等から好ましい。BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, the present invention will be described in detail.
Lactoperoxidase and lactoferrin used in the present invention are derived from milk of mammals such as cow's milk, human milk, goat's milk and sheep's milk. Lactoperoxidase and lactoferrin contain a large amount of basic amino acids such as lysine and arginine, and are sometimes collectively called basic proteins. This basic protein can be obtained by purifying milk raw materials such as skim milk and whey using a cation exchange resin. After separating and purifying lactoperoxidase and lactoferrin, respectively, from milk, each can be blended according to the required amount.In particular, it contains lactoperoxidase and lactoferrin obtained using skim milk or whey of milk as a raw material. It is preferable to use a basic protein fraction from the viewpoint of economy and the like.
【０００７】この塩基性タンパク質画分を得る方法とし
ては、乳又は乳由来の原料を陽イオン交換体に接触させ
て塩基性タンパク質を吸着させた後、この陽イオン交換
体に吸着した塩基性タンパク質画分を、pH5を越え、イ
オン強度0.5を越える溶出液で溶出して得る方法（特開
平5-202098号公報）、アルギン酸ゲルを用いて得る方法
（特開昭61-246198号公報）、無機の多孔性粒子を用い
て乳清から得る方法（特開平1-86839号公報）、硫酸化
エステル化合物を用いて乳から得る方法（特開昭63-255
300号公報）等が知られており、本発明では、このよう
な方法で得られた塩基性タンパク質画分を用いることが
できる。[0007] As a method for obtaining the basic protein fraction, milk or a milk-derived raw material is contacted with a cation exchanger to adsorb the basic protein, and then the basic protein adsorbed to the cation exchanger is adsorbed. A method in which a fraction is eluted with an eluate exceeding pH 5 and an ionic strength of more than 0.5 (JP-A-5-202098), a method using an alginate gel (JP-A-61-246198), (Japanese Patent Application Laid-Open No. 1-86839), a method for obtaining from milk using a sulfated ester compound (Japanese Patent Application Laid-Open No. 63-255)
No. 300) is known, and in the present invention, a basic protein fraction obtained by such a method can be used.
【０００８】ラクトパーオキシダーゼ及びラクトフェリ
ンは、肝機能改善剤中においては、それぞれを単独で配
合するのではなく、併用して配合することがさらに好ま
しく、併用することによって、より強い肝機能改善作用
を発揮することができる。[0008] Lactoperoxidase and lactoferrin are more preferably used in combination with each other in the liver function improving agent, instead of being used alone, and are more preferably used in combination. Can be demonstrated.
【０００９】本発明者らは、成人において、固形物換算
でラクトパーオキシダーゼを0.1mg/日以上、及び固形物
換算でラクトフェリンを0.1g/日以上摂取することが望
ましいことを確認している。したがって、ラクトパーオ
キシダーゼ及びラクトフェリンについては、肝機能改善
作用を付与した飲食品に固形物換算でラクトパーオキシ
ダーゼを0.1mg/100g 以上、及び固形物換算でラクトフ
ェリンを0.1g/100g以上配合することが望ましい。The present inventors have confirmed that it is desirable for an adult to take lactoperoxidase at a dose of 0.1 mg / day or more on a solid basis and 0.1 g / day or more of lactoferrin on a solid basis. Therefore, for lactoperoxidase and lactoferrin, lactoperoxidase is 0.1 mg / 100 g or more in terms of solids and lactoferrin 0.1 g / 100 g or more in terms of solids is added to the food or drink provided with the liver function improving effect. desirable.
【００１０】本発明の肝機能改善剤においては、ラクト
パーオキシダーゼやラクトフェリンを単独で用いてもよ
く、また、他の成分といっしょに用いてもよく、使用目
的や方法等に応じて、粉末状、液状、タブレット状等の
形状に製剤化すればよい。[0010] In the liver function improving agent of the present invention, lactoperoxidase or lactoferrin may be used alone, or may be used together with other components. It may be formulated into a liquid, tablet, or other form.
【００１１】また、本発明の肝機能改善剤については、
栄養組成物の形態として、タンパク質、糖質、脂質、ビ
タミン類及びミネラル類等を主成分として構成すること
もできる。[0011] Further, the liver function improving agent of the present invention includes:
As a form of the nutritional composition, proteins, carbohydrates, lipids, vitamins, minerals, and the like can be mainly composed.
【００１２】タンパク質としては、カゼイン、乳清タン
パク質濃縮物（ＷＰＣ）、乳清タンパク質分離物（ＷＰ
Ｉ）、αs-カゼイン、β−カゼイン、α−ラクトアルブ
ミン及びβ−ラクトグロブリン等の乳タンパク質分画
物、大豆タンパク質や小麦タンパク質等の植物タンパク
質等を挙げることができ、さらには、これらのタンパク
質を酸や酵素で処理して、ペプチドあるいは遊離アミノ
酸の形態で用いてもよい。なお、遊離アミノ酸は、窒素
源としての他に、特定の生理作用を付与するために用い
ることもでき、それらのアミノ酸としては、タウリン、
シスチン、システイン、アルギニン、グルタミン等を挙
げることができる。これらのタンパク質やペプチド、あ
るいは遊離アミノ酸は、栄養組成物の固形分当たり 5〜
30重量％配合することが好ましい。Examples of proteins include casein, whey protein concentrate (WPC), whey protein isolate (WP
I), milk protein fractions such as αs-casein, β-casein, α-lactalbumin and β-lactoglobulin, and plant proteins such as soybean protein and wheat protein, and the like. May be treated with an acid or an enzyme and used in the form of a peptide or a free amino acid. In addition, a free amino acid can also be used for giving a specific physiological effect in addition to a nitrogen source, and as those amino acids, taurine,
Cystine, cysteine, arginine, glutamine and the like can be mentioned. These proteins and peptides, or free amino acids, are present in the nutrient composition at 5 to
It is preferable to add 30% by weight.
【００１３】糖質としては、デンプン、可溶性多糖類、
デキストリン、ショ糖、乳糖、麦芽糖、ぶどう糖等や、
ガラクトシルラクトース、フラクトオリゴ糖、ラクチュ
ロース等のオリゴ糖、あるいは人工甘味料等を挙げるこ
とができる。糖質は、栄養組成物の固形分当たり、40〜
80重量％配合することがが好ましい。The saccharides include starch, soluble polysaccharide,
Dextrin, sucrose, lactose, maltose, glucose, etc.,
Oligosaccharides such as galactosyl lactose, fructooligosaccharides and lactulose, and artificial sweeteners can be mentioned. Carbohydrate is 40 to 40 per solid content of the nutritional composition.
It is preferable to mix 80% by weight.
【００１４】脂質としては、乳脂肪、ラード、牛脂及び
魚油等の動物性油脂、大豆油、菜種油、コーン油、月見
草油、中鎖脂肪酸トリグリセリド（ＭＣＴ）及び綿実油
等の植物性油脂、さらには、それらの分別油、水添油、
エステル交換油等を挙げることができる。脂質は、栄養
組成物の固形分当たり40重量％以下配合することが好ま
しい。The lipids include animal fats and oils such as milk fat, lard, beef tallow and fish oil, soybean oil, rapeseed oil, corn oil, evening primrose oil, vegetable fats and oils such as medium chain fatty acid triglyceride (MCT) and cottonseed oil. Those fractionated oils, hydrogenated oils,
Transesterified oils and the like can be mentioned. It is preferable that the lipid is incorporated in an amount of 40% by weight or less per solid content of the nutritional composition.
【００１５】ビタミン類及びミネラル類については、食
品衛生法に基づく指定添加物（施行規則別表第２に収載
の添加物）及び既存添加物（既存添加物名簿に収載の添
加物）のビタミン類及びミネラル類を用いればよい。ビ
タミン類の具体例としては、ビタミンＡ、ビタミンＢ
類、ビタミンＣ、ビタミンＤ、ビタミンＥ、ビタミンＫ
類、葉酸、パントテン酸、β−カロチン、ニコチン酸ア
ミド、ビオチン、イノシトール、コリン等を挙げること
ができ、栄養組成物の固形分当たり0.01〜5重量％配合
することが好ましい。また、ミネラル類の具体例として
は、カルシウム、マグネシウム、カリウム、ナトリウ
ム、リン、塩素、鉄、銅、亜鉛、ヨウ素、マンガン、セ
レン、フッ素、クロム、モリブデン等を挙げることがで
き、栄養組成物の固形分当たり0.001〜5重量％配合する
ことが好ましい。With respect to vitamins and minerals, the additives and additives specified in the Food Sanitation Act (additives listed in Appendix 2 of the Enforcement Regulations) and existing additives (additives listed in the list of existing additives) Minerals may be used. Specific examples of vitamins include vitamin A, vitamin B
, Vitamin C, vitamin D, vitamin E, vitamin K
, Folic acid, pantothenic acid, β-carotene, nicotinamide, biotin, inositol, choline and the like, and preferably 0.01 to 5% by weight based on the solid content of the nutritional composition. Specific examples of the minerals include calcium, magnesium, potassium, sodium, phosphorus, chlorine, iron, copper, zinc, iodine, manganese, selenium, fluorine, chromium, molybdenum, and the like. It is preferable to add 0.001 to 5% by weight per solid content.
【００１６】さらに、本発明の肝機能改善作用を付与し
た飲食品としては、チーズ、バター及び発酵乳等の乳食
品、乳飲料、ドリンクヨーグルト、コーヒー飲料及び果
汁等の飲料、ゼリー、プリン、クッキー、ビスケット及
びウエハース等の菓子、さらには、冷凍食品等の各種飲
食品が挙げられる。次に、実施例を示して本発明を詳細
に説明する。The foods and drinks provided with the liver function improving effect of the present invention include milk foods such as cheese, butter and fermented milk, milk drinks, drink yogurt, coffee drinks, fruit juices and other drinks, jellies, puddings and cookies. , Biscuits, confectionery such as wafers, and various foods and beverages such as frozen foods. Next, the present invention will be described in detail with reference to examples.
【００１７】[0017]
【実施例１】（肝機能改善剤の製造）牛乳由来のラクト
パーオキシダーゼ（シグマ社製） 0.1mg、及び牛乳由来
のラクトフェリン（シグマ社製） 100mgに、含水結晶ぶ
どう糖 93.4g、炭酸カルシウム5g、シュガーエステル1
g、香料0.5gを加え、混和した後、タブレット状に打錠
し、肝機能改善剤を製造した。Example 1 Production of Liver Function Improving Agent 0.1 mg of milk-derived lactoperoxidase (manufactured by Sigma) and 100 mg of milk-derived lactoferrin (manufactured by Sigma) were mixed with 93.4 g of hydrous glucose, 5 g of calcium carbonate, Sugar ester 1
g and a perfume (0.5 g) were added and mixed, followed by tableting to produce a liver function improving agent.
【００１８】[0018]
【実施例２】（肝機能改善作用を付与した乳飲料）脱脂
乳をＣＭセファロース（ファルマシア社製）に接触さ
せ、吸着した画分を１Ｍの食塩水で溶出し、電気透析を
行って脱塩した後、濃縮及び凍結乾燥することにより得
た塩基性タンパク質画分を、 1 l当たり1gとなるよう
に生乳に添加し、圧力120kg/cm2でホモゲナイズした
後、 120℃で４秒間加熱殺菌して、肝機能改善作用を付
与した乳飲料を製造した。なお、この乳飲料には、 100
ml当たりラクトパーオキシダーゼ12mg及びラクトフェリ
ン12mgが含まれていた。Example 2 (Milk drink with liver function improving action) Contact skim milk with CM Sepharose (manufactured by Pharmacia), elute the adsorbed fraction with 1M saline, and perform electrodialysis to desalinate. After that, the basic protein fraction obtained by concentration and freeze-drying was added to raw milk at a concentration of 1 g per liter, homogenized at a pressure of 120 kg / cm 2 , and then sterilized by heating at 120 ° C. for 4 seconds. Thus, a milk beverage having a liver function improving effect was produced. This milk drink has 100
It contained 12 mg lactoperoxidase and 12 mg lactoferrin per ml.
【００１９】[0019]
【実施例３】（肝機能改善作用を付与したヨーグルト）
脱脂粉乳を固形率12％となるように水に溶解し、90℃で
20分間加熱殺菌した後、25℃に冷却し、乳酸菌であるラ
クトバチルス・アシドフィルス（L.acidophilus）とス
トレプトコッカス・サーモフィルス（S.thermophilus）
を接種した。そして、乳酸酸度が 1.0％、pHが 4.3にな
った時点で 5℃に冷却した。さらにチーズホエーをＣＭ
セファロース（ファルマシア社製）に接触させ、吸着し
た画分を１Ｍの食塩水で溶出し、電気透析を行って脱塩
した後、濃縮及び凍結乾燥することにより得た塩基性タ
ンパク質画分1.5gを添加した。このようにして調製した
スターターカルチャーを、115℃で2秒間加熱殺菌した脂
肪率 3.5％の生乳に 5重量％接種し、発酵及び冷却を常
法に従って行い、肝機能改善作用を付与したヨーグルト
を製造した。なお、このヨーグルトには、100g当たりラ
クトパーオキシダーゼ12mg及びラクトフェリン12mgが含
まれていた。次に、動物実験により効果を確認した試験
例を示す。Example 3 (Yogurt with liver function improving action)
Dissolve skim milk powder in water so as to have a solid content of 12%.
After heat sterilization for 20 minutes, it is cooled to 25 ° C and lactic acid bacteria Lactobacillus acidophilus ( L. acidophilus) and Streptococcus thermophilus ( S. thermophilus )
Was inoculated. Then, when the lactic acidity reached 1.0% and the pH reached 4.3, the mixture was cooled to 5 ° C. In addition, CM cheese whey
After contacting with Sepharose (manufactured by Pharmacia), the adsorbed fraction was eluted with 1 M saline, subjected to electrodialysis, desalted, concentrated and lyophilized to obtain 1.5 g of a basic protein fraction. Was added. The starter culture thus prepared is heat-sterilized at 115 ° C for 2 seconds, inoculated at 5% by weight into raw milk with a fat percentage of 3.5%, fermented and cooled according to a conventional method to produce yogurt with liver function improving action. did. In addition, this yogurt contained 12 mg of lactoperoxidase and 12 mg of lactoferrin per 100 g. Next, a test example in which the effect was confirmed by an animal experiment will be described.
【００２０】[0020]
【試験例１】動物用飼料として、表１に示す４種の試験
食を作成した。なお、ラクトパーオキシダーゼは LPOと
表示し、ラクトフェリンはLFと表示した。Test Example 1 Four kinds of test meals shown in Table 1 were prepared as animal feeds. Lactoperoxidase is indicated as LPO, and lactoferrin is indicated as LF.
【００２１】[0021]
【表１】 [Table 1]
【００２２】肝機能障害モデルラットは、常法に従っ
て、四塩化炭素を用いて作成した。すなわち、 4週齢SD
系雄ラットを 1群 8匹に分け、24時間絶食後、1ml/kg用
量で10％四塩化炭素溶液（v/v,パナセート 800）を腹腔
内投与して作成した。このモデルラットに、表１に組成
を示した動物用飼料を与え、４週間飼育した後、血清中
のグルタミン酸-オキザロ酢酸トランスアミナーゼ（GO
T）活性及びグルタミン酸-ピルビン酸トランスアミナー
ゼ（GPT）活性を測定することで、肝機能改善作用を評
価した。その結果を表２に示す。Hepatic dysfunction model rats were prepared using carbon tetrachloride according to a conventional method. That is, 4 weeks old SD
The male rats were divided into 8 rats per group, and after a 24-hour fast, a 10% carbon tetrachloride solution (v / v, Panassate 800) was intraperitoneally administered at a dose of 1 ml / kg. This model rat was fed an animal feed having the composition shown in Table 1 and bred for 4 weeks, and then glutamic acid-oxaloacetate transaminase (GO) in serum.
T) The activity of improving liver function was evaluated by measuring the activity and the activity of glutamate-pyruvate transaminase (GPT). Table 2 shows the results.
【００２３】[0023]
【表２】 [Table 2]
【００２４】これによると、血清中のGOT活性及びGPT活
性は、対照食群に比べ、LPO食群、LF食群及びLPO・LF食
群で有意に低下していることが認められ、肝機能改善作
用を有することがわかった。According to this, GOT activity and GPT activity in the serum were found to be significantly lower in the LPO, LF and LPO / LF diet groups than in the control diet group, and liver function was confirmed. It was found to have an improving effect.
【００２５】[0025]
【発明の効果】本発明に使用するラクトパーオキシダー
ゼ及びラクトフェリンは、四塩化炭素による急性の肝機
能障害に対して肝機能改善作用を有するだけでなく、安
全性が高いので、それらを配合した本発明の肝機能改善
剤及び肝機能改善作用を付与した飲食品は、長期的摂取
が可能で、肝機能の改善に有用である。The lactoperoxidase and lactoferrin used in the present invention not only have an effect of improving liver function against acute liver dysfunction caused by carbon tetrachloride, but also have high safety. The liver function-improving agent and the food or drink provided with the liver function-improving action of the present invention can be taken for a long time and are useful for improving liver function.
Claims (2)
トフェリンを有効成分とすることを特徴とする肝機能改
善剤。1. A liver function improving agent comprising lactoperoxidase and / or lactoferrin as an active ingredient.
トフェリンを配合して肝機能改善作用を付与した飲食
品。2. A food or drink which is mixed with lactoperoxidase and / or lactoferrin to impart a liver function improving effect.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000038486A JP4679687B2 (en) | 2000-02-16 | 2000-02-16 | Liver function improving agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000038486A JP4679687B2 (en) | 2000-02-16 | 2000-02-16 | Liver function improving agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001226289A true JP2001226289A (en) | 2001-08-21 |
| JP4679687B2 JP4679687B2 (en) | 2011-04-27 |
Family
ID=18562215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000038486A Expired - Fee Related JP4679687B2 (en) | 2000-02-16 | 2000-02-16 | Liver function improving agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4679687B2 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004331564A (en) * | 2003-05-07 | 2004-11-25 | Snow Brand Milk Prod Co Ltd | Skin collagen production enhancer |
| JP2004331565A (en) * | 2003-05-07 | 2004-11-25 | Snow Brand Milk Prod Co Ltd | Skin collagen production enhancer |
| WO2005094848A1 (en) * | 2004-03-31 | 2005-10-13 | Calpis Co., Ltd. | Agent for preventing or suppressing hepatopathy and functional food for preventing or suppressing hepatopathy |
| EP1598076A1 (en) * | 2003-02-24 | 2005-11-23 | Morinaga Milk Industry Co., Ltd. | Interleukin 6 production inhibitor |
| JP2008533134A (en) * | 2005-03-15 | 2008-08-21 | キャンピナ・ネダーランド・ホールディング・ビー．ブイ． | Dermatological use of milk protein |
| JP2009215301A (en) * | 2009-04-27 | 2009-09-24 | Morinaga Milk Ind Co Ltd | Protease inhibitor |
| US7932069B2 (en) | 2004-02-17 | 2011-04-26 | Morinaga Milk Industry Co., Ltd. | Process for producing lactoperoxidase |
| EP2668851A1 (en) | 2012-05-29 | 2013-12-04 | Ueno Fine Chemicals Industry, Ltd. | Liver function-improving agent |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05124980A (en) * | 1991-10-30 | 1993-05-21 | Snow Brand Milk Prod Co Ltd | Aging preventing agent |
| JPH06145068A (en) * | 1992-04-02 | 1994-05-24 | Imuno Japan:Kk | Biophylaxis enhancer, medicine for improvement of infectious disease and biophylaxis enhancing food |
| JPH09107917A (en) * | 1995-10-17 | 1997-04-28 | Snow Brand Milk Prod Co Ltd | Low cariogenic nutritive composition |
| JPH1175770A (en) * | 1997-09-09 | 1999-03-23 | Bizen Kasei Kk | Peroxylipid production inhibitor, its production and utulization thereof |
| WO2000006192A1 (en) * | 1998-07-30 | 2000-02-10 | Morinaga Milk Industry Co., Ltd. | Liver function ameliorating agents |
-
2000
- 2000-02-16 JP JP2000038486A patent/JP4679687B2/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05124980A (en) * | 1991-10-30 | 1993-05-21 | Snow Brand Milk Prod Co Ltd | Aging preventing agent |
| JPH06145068A (en) * | 1992-04-02 | 1994-05-24 | Imuno Japan:Kk | Biophylaxis enhancer, medicine for improvement of infectious disease and biophylaxis enhancing food |
| JPH09107917A (en) * | 1995-10-17 | 1997-04-28 | Snow Brand Milk Prod Co Ltd | Low cariogenic nutritive composition |
| JPH1175770A (en) * | 1997-09-09 | 1999-03-23 | Bizen Kasei Kk | Peroxylipid production inhibitor, its production and utulization thereof |
| WO2000006192A1 (en) * | 1998-07-30 | 2000-02-10 | Morinaga Milk Industry Co., Ltd. | Liver function ameliorating agents |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1598076A4 (en) * | 2003-02-24 | 2008-07-09 | Morinaga Milk Industry Co Ltd | Interleukin 6 production inhibitor |
| US7282202B2 (en) | 2003-02-24 | 2007-10-16 | Morinaga Milk Industry Co., Ltd. | Interleukin-6 suppressive agent |
| US7731955B2 (en) | 2003-02-24 | 2010-06-08 | Morinaga Milk Industry Co., Ltd. | Interleukin-6 suppressive agent |
| EP1598076A1 (en) * | 2003-02-24 | 2005-11-23 | Morinaga Milk Industry Co., Ltd. | Interleukin 6 production inhibitor |
| JP2004331564A (en) * | 2003-05-07 | 2004-11-25 | Snow Brand Milk Prod Co Ltd | Skin collagen production enhancer |
| JP2004331565A (en) * | 2003-05-07 | 2004-11-25 | Snow Brand Milk Prod Co Ltd | Skin collagen production enhancer |
| JP4698934B2 (en) * | 2003-05-07 | 2011-06-08 | 雪印乳業株式会社 | Skin collagen production promoter |
| US7932069B2 (en) | 2004-02-17 | 2011-04-26 | Morinaga Milk Industry Co., Ltd. | Process for producing lactoperoxidase |
| JPWO2005094848A1 (en) * | 2004-03-31 | 2008-02-14 | カルピス株式会社 | Liver disorder preventive or inhibitor and functional food for preventing or suppressing liver disorder |
| WO2005094848A1 (en) * | 2004-03-31 | 2005-10-13 | Calpis Co., Ltd. | Agent for preventing or suppressing hepatopathy and functional food for preventing or suppressing hepatopathy |
| JP2008533134A (en) * | 2005-03-15 | 2008-08-21 | キャンピナ・ネダーランド・ホールディング・ビー．ブイ． | Dermatological use of milk protein |
| JP2009215301A (en) * | 2009-04-27 | 2009-09-24 | Morinaga Milk Ind Co Ltd | Protease inhibitor |
| EP2668851A1 (en) | 2012-05-29 | 2013-12-04 | Ueno Fine Chemicals Industry, Ltd. | Liver function-improving agent |
| US9155752B2 (en) | 2012-05-29 | 2015-10-13 | Ueno Fine Chemicals Industry, Ltd. | Liver function-improving agent |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4679687B2 (en) | 2011-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Walzem et al. | Whey components: millennia of evolution create functionalities for mammalian nutrition: what we know and what we may be overlooking | |
| KR101038354B1 (en) | Nutritional compositions | |
| Korhonen | Bioactive components in bovine milk | |
| JP2001158736A (en) | Agent for preventing and improving osteoarthropathy | |
| Chandan | Role of milk and dairy foods in nutrition and health | |
| Gupta | Whey Proteins: A Novel Source of Bioceuticals' Charu Gupta,“Dhan Prakash,“Amar P. Garg and “Sneh Gupta" Amity Institute of Herbal Research and Studies, Amity University, Noida, India “Department of Microbiology, CCS University, Meerut (UP), India" Department of Zoology, RG (PG) College, Chippi Tank, Meerut (UP), India | |
| EP1228708B1 (en) | Milk derived basic protein fraction as agents for reducing high blood pressure | |
| JP5173230B2 (en) | Amino acid composition and food and drink | |
| Ahmad | Buffalo milk | |
| JP4034370B2 (en) | Brain function improving agent and nutritional composition | |
| JP6093300B2 (en) | Composition for preventing and / or improving irreversible metabolic disorders associated with cancer | |
| JP4679687B2 (en) | Liver function improving agent | |
| JP6037595B2 (en) | Satiety induction composition and method for producing the same | |
| CN111201026B (en) | Fermented milk and polysaccharides with cancer cachexia inhibiting effect | |
| JP3613488B2 (en) | Nutritional composition | |
| WO2019235451A1 (en) | Composition for treatment of menstrual symptom | |
| JP2004115509A (en) | Osteoprotegerin inhibitory factor production promoter | |
| Tiwari et al. | Nutritional Values and Therapeutic Uses of Capra hircus Milk. | |
| WO2012102100A1 (en) | Sense-improving agent | |
| Kumar et al. | Bioactive and functional ingredients from dairy products | |
| JPH1014534A (en) | Nutritive composition | |
| JP3789146B2 (en) | Oligosaccharide-containing nutritional composition | |
| WO2017126645A1 (en) | Composition for inhibiting migration of endotoxin into blood | |
| Madureira et al. | Functional dairy ingredients | |
| Park | Bioactive components in cow's milk |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070215 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100226 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100421 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20100421 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100810 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101004 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101021 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110126 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110202 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4679687 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140210 Year of fee payment: 3 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140210 Year of fee payment: 3 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140210 Year of fee payment: 3 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140210 Year of fee payment: 3 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| LAPS | Cancellation because of no payment of annual fees |